Novavax Aktie
WKN DE: A2PKMZ / ISIN: US6700024010
06.08.2025 23:13:09
|
Novavax (NVAX) Profit Jumps on Milestone
Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment linked to U.S. regulatory approval of its COVID-19 vaccine. Revenue (GAAP) reached $239 million, ahead of analyst expectations of $152.61 million, while diluted earnings per share (GAAP) came in at $0.62, well above the expected loss of $0.04. While the company beat expectations decisively, its business model is in transition, with product sales falling sharply and partnership revenues comprising the bulk of results this period. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the development of recombinant protein-based vaccines, including its COVID-19 shot and the adjuvant Matrix-M, which enhances immune responses. Its core offering, Nuvaxovid, is the only recombinant protein-based, non-messenger RNA (mRNA) COVID-19 vaccine currently available in the U.S.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novavax Inc.mehr Nachrichten
05.08.25 |
Ausblick: Novavax zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Novavax Inc.mehr Analysen
Aktien in diesem Artikel
Novavax Inc. | 7,60 | -2,92% |
|